Plasma Protease C1-inhibitor Treatment: Global Strategic Business Report

Global Plasma Protease C1-inhibitor Treatment Market to Reach $16.1 Billion by 2030

The global market for Plasma Protease C1-inhibitor Treatment estimated at US$3.8 Billion in the year 2022, is projected to reach a revised size of US$16.1 Billion by 2030, growing at a CAGR of 20% over the analysis period 2022-2030. C1-Inhibitor, one of the segments analyzed in the report, is projected to record 18.2% CAGR and reach US$7.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Kallikrein Inhibitor (Kalbitor) segment is readjusted to a revised 20.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 19.1% CAGR

The Plasma Protease C1-inhibitor Treatment market in the U.S. is estimated at US$1.1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.7 Billion by the year 2030 trailing a CAGR of 19.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.7% and 17.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 14.7% CAGR.

Select Competitors (Total 46 Featured) -

• AbbVie
• Alexion
• Argenx
• Bluebird Bio
• Bristol-Myers Squibb/Celgene
• CSL Limited
• FibroGen
• Gilead
• GlaxoSmithKline
• Novartis
• Pharming Group N.V.
• Sanquin
• Shire plc
• Vertex

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and the publisher's Research Platform
• Complimentary updates for one year